ArticleAlzheimer's research & therapy2026
An RNA biomarker panel for the diagnosis of Alzheimer's disease from whole blood.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer’s Disease (AD) diagnosis remains primarily clinical, relying on patient history, cognitive tests, and sometimes brain imaging. Emerging approaches include advanced neuroimaging techniques and the use of protein biomarkers in cerebrospinal fluid and plasma. However, these methods have limitations such as high costs and the need for specialized infrastructures. In contrast, analysis of RNA expression in blood samples could be achieved with a high degree of sensitivity and accuracy in point of care settings, providing an ideal platform for a timely and accurate AD diagnosis.
methodsPeripheral blood samples from 50 AD patients and 50 healthy subjects were analyzed utilizing a whole transcriptome RNA sequencing approach to determine differences in the expression of (i) mRNAs, (ii) lncRNAs, (iii) miRNAs, (iv) circRNAs and (v) alternatively spliced mRNA isoforms. Multiple parallel analysis pipelines were utilized to identify a set of putative RNA biomarkers. A two-step validation assay was utilized to identify differentially expressed transcripts and form an AD RNA biomarker panel.
resultsThe final Alzheimer’s disease (AD) panel includes only mRNAs, as non-coding RNAs lacked sufficient robustness in whole blood for clinical translation under our criteria. Expression levels of the four selected RNA biomarkers in each AD patient were compared with those in healthy controls to calculate an AD predictive score (ADps), achieving a positive predictive value above 90% and specificity exceeding 95%.
conclusionsThe four RNA biomarkers can reliably identify Alzheimer’s disease (AD) patients using a small amount of peripheral blood and show strong potential as a minimally invasive, cost-effective tool for early diagnosis. However, their predictive accuracy and discriminative power may be more precisely established through analysis of a larger, well-defined AD cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.